In accordance with an abundance of literature indicating the oncogenic role of EGFR and ERBB2, these two family members each have a greater than three-fold higher incidence of somatic alterations compared to ERBB3 or ERBB4. Nevertheless, the frequency rate of somatic alterations of EGFR account for only 5.6% of all cancer types, with other ERBB family members having a lower rate of somatic alterations within the GENIE dataset [9]. The gene discussed is EGFR; the disease is cancer.